Sernova Corp T.SVA

Sigilon

[BioTeck]

Sigilon Therapeutics went public today and is trading at $28.00. Adjusted for our surplus of outstanding shares (thanks management), we should be well over $2 considering we have everything they have and more.

Does management have what it takes to get SVA to fair value? It's now or never.

[elgin1]

The fact Siligon has Lilly and Black Rock backing them with $100 million financing and exercised all their options tells me Siligon is not far way from success.  Any positive clinical development from Siligon will be very detrimental to Sva imo. They have the funds and management to succeed .   Unless management can get collaboration with pharma with money along with it , you can say

[Redbaron2211]

I see this as bullish.  Sigilon is going after Hemophilia and started their trial a couple months ago recruiting 9 patients .  They are preclinical on diabetes.  This puts a floor in for what we should be valued at with our hemophilia potential..  El  Lilly has been backing Sigilon; this isn't new. I remember a couple years ago they dumped 60mil into sig.   The

[BioTeck]

Market doesn't know Philips hand? Sernova is still giving away free pouches and 2 year try before you buy deals. I'm with Elgin, this is not good news for Sernova. I mentioned the rabbit and hare analogy a long time ago and it's coming to fruition. Sernova was ahead of the pack by a lot. They made lots of poor decisions and gave away pouches for free for years and got nothing in return

[Redbaron2211]

Bio you said the exact same thing about Viacyte.  Then it was Vertex and yet still after all these years here we sit the only ones in the clinic showing positive results.  That's a fact.  So let's just keep talking about poor decisions and that Trout solesbury the Leading IR in specialty pharma and medical device companies was used by two companies in that field. What

[Sonny7]

Vasquez, Trout, and more, all hired when all Sernova could show was a piece of plastic and an idea, so how the hell is anyone going to promote “nothing”? That speaks to the worthlessness of Matthews and a doctor who has no business sense, being led around by the halfwit. It’s plain to see that the tail is and has been wagging the dog here and it doesn’t seem like it will change. If only one of

[Metalsguy1]

WHAT IN THE EVER LOVING FU#K IS GOING ON. I complete agree with Biotechnology and Elgin on their comments but has anyone noted who the IR firm is for SIGILON??? Somebody Trout yup...between the fact Trout is in their with Black Rock and Lilly and massive financial backing is seriously looking bad for SVA if management does not cinch some high profile publicly disclosed deals soon. With shoddy and,

[BioTeck]

Finally, I was getting tired of being the only one questioning management and not only focussing on the positives of SVA. Count me in MetalsGuy, I have a sizeable holding and will gladly use my votes to change management. They have done NOTHING for the investors for years. 30 cents is the PP price folks, lets not get too excited here. Big pharma has a clear window into SVA's data. Phil and

[Redbaron2211]

I'm not defending poor decisions.  Just calling out dumb logic.   Sure they have lots of money now, show us the science.  The moment Vertex or Sigilion starts their TD1 FDA trial then you can start harping. None of you actually know what Philip has disclosed to Pharma your "probably comparing data" sounds as reliable as the trout conspiracy.  Why don

[Metalsguy1]

I think the main point is that prior decisions and questionable financing practices have indeed cast a shadow over SVA. A hundred million puts others in a Ferrari heading for a huge payoff, while Sernova is puttering down the road in a Yugo with 5 patients strapped to the roof. Consider this. Clearly Lilly et al have a very high level of confidence in Sigilon. If they got taken out like Semma at